# Antimicrobial Susceptibility Testing Guided Triple Therapy in Salvage Helicobacter Pylori Treatment

> **NCT03139253** · PHASE4 · UNKNOWN · sponsor: **Yanqing Li** · enrollment: 120 (estimated)

## Conditions studied

- Antimicrobial Susceptibility Testing
- Triple Therapy

## Interventions

- **DRUG:** amoxicillin
- **DRUG:** clarithromycin
- **DRUG:** tinidazole
- **DRUG:** levofloxacin
- **DRUG:** furazolidone
- **DRUG:** tetracycline
- **DRUG:** Ilaprazole

## Key facts

- **NCT ID:** NCT03139253
- **Lead sponsor:** Yanqing Li
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-05-30
- **Primary completion:** 2017-06-30
- **Final completion:** 2017-06-30
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2017-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03139253

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03139253, "Antimicrobial Susceptibility Testing Guided Triple Therapy in Salvage Helicobacter Pylori Treatment". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03139253. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*